Important end point for clinical trials...Ellipsoid Zone loss....using these analyses, we will be able to identify early progressors and treatment response.
Excited to share that Netramind Innovations has developed an advanced AI solution for drusen area measurements, geographic atrophy measurements, and ellipsoid zone measurements—recently recognized as a clinical trial endpoint by the #FDA. This breakthrough technology streamlines retinal disease analysis and supports more accurate and efficient clinical trials. Proud to see how AI is revolutionizing ophthalmology and advancing patient care! #AI #Ophthalmology #ClinicalTrials #Innovation #NetramindInnovations #Retina #FDA #HealthcareTechnology #AMD #Retina Jay Chhablani Kiran Vupparaboina Sandeep Chandra Choroidal Analysis Research Lab
Very helpful
Subijay Sinha
4 个月
Great advice
PhD Candidate | Clinical Research Fellow, Department of Ophthalmology & Visual Sciences, University of British Columbia
4 个月Good to know!